Attovia Therapeutics

News

Two more biotechs, Attovia and Braveheart, join the IPO line

The steady stream of biotechs aiming to list on the Nasdaq has continued, with Attovia and Braveheart the latest to make their intentions known.

News

Merida raises $121m for Graves drug, and other financings

Our round-up of recent biotech financings includes rounds for Merida, Glycomine, Attovia, Imbria, and Solu Therapeutics.

News

TIGIT developer iTeos raises $120m, and other financings

Our round-up of notable biotech financings in the last week includes a $120 million direct offering for immunology and inflammation biotech iTeos, and private rounds for L

Two more biotechs, Attovia and Braveheart, join the IPO line

Merida raises $121m for Graves drug, and other financings

TIGIT developer iTeos raises $120m, and other financings

Policy in Focus: What’s new with CMS drug price negotiation,...

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks